Company Filing History:

10 out of 1,500

Astrazeneca Ab

Imperial Chemical Industries Limited

where one patent can have more than one assignee

Years Active: 1995-2007

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7176212 - 2,4-diamino pyrimidine compounds having anti-cell proliferative activity (2007-02-13),

2. 7153964 - Pyrimidine compounds (2006-12-26),

3. 6969714 - Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation (2005-11-29),

4. 6855719 - Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives (2005-02-15),

5. 6787562 - Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists (2004-09-07),

6. 6716831 - 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity (2004-04-06),

7. 6710052 - Pyrimidine compounds (2004-03-23),

8. 6670368 - Pyrimidine compounds with pharmaceutical activity (2003-12-30),

9. 6649608 - 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents (2003-11-18),

10. 6632820 - Pyrimidine compounds (2003-10-14),

11. 6593326 - 2,4-diamino pyrimidine compounds having anti-cell proliferative activity (2003-07-15),

12. 6365603 - Aromatic compounds and pharmaceutical compositions containing them (2002-04-02),

13. 6313148 - Aromatic amine compounds that antagnoize the pain enhancing effects of prostaglandins (2001-11-06),

14. 6100258 - Aromatic amine compounds that antagonize the pain enhancing effects of (2000-08-08),

15. 6057345 - Substituted aryl and heteroaryl compounds as E-type prostaglandin (2000-05-02),

Title: Gloria Anne Breault: Innovator in Anti-Cancer Pharmaceuticals

Introduction: Gloria Anne Breault, a distinguished inventor located in Macclesfield, GB, has significantly contributed to the field of pharmaceuticals through her innovative work in pyrimidine compounds. With a remarkable total of 21 patents to her name, her research primarily focuses on compounds with anti-cell proliferative activity, particularly in the area of cancer treatment.

Latest Patents: Among her latest inventions is a patent involving 2,4-diamino pyrimidine compounds that demonstrate anti-cell proliferative activity. This patent describes a pyrimidine derivative of formula (I), wherein substituents and structures promote their effectiveness as anti-cancer agents. Another notable patent involves pyrimidine derivatives that serve as cyclin-dependent serine/threonine kinase (CDK) inhibitors, essential in various pharmaceutical compositions aimed at treating cancer. These patents detail various medicinal uses and the processes for synthesizing these compounds.

Career Highlights: Gloria has made significant strides in her career while working with prominent pharmaceutical companies such as AstraZeneca and Zeneca Limited. Her research contributions have advanced understanding in the pharmaceutical sciences, especially in developing effective cancer treatments.

Collaborations: Throughout her career, Gloria has collaborated with esteemed professionals, including Janet Elizabeth Pease and Howard Tucker. These associations have fostered a collaborative environment that has led to groundbreaking developments in the pharmaceutical field.

Conclusion: Gloria Anne Breault's work embodies the spirit of innovation in the pharmaceutical industry, particularly in her contributions to anti-cancer agents through her extensive patent portfolio. Her dedication to research and development continues to inspire future advancements in medicine, proving essential for the ongoing battle against cancer.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com